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Abstract
Aim: To evaluate the use of recombinant human fibroblast growth factor (rhFGF)- 2 in 
combination with deproteinized bovine bone mineral (DBBM) compared with rhFGF-
 2 alone, in the treatment of intrabony periodontal defects.
Materials and Methods: Patients with periodontitis who had received initial periodon-
tal therapy and had intrabony defects of ≥ 3 mm in depth were enrolled. Sites were 
randomly assigned to receive a commercial formulation of 0.3% rhFGF- 2 + DBBM (test) 
or rhFGF- 2 alone (control). Clinical parameters and a patient- reported outcome meas-
ure (PROM) were evaluated at baseline and at 3 and 6 months postoperatively.
Results: Twenty- two sites in each group were evaluated. A significant improvement 
in clinical attachment level (CAL) from baseline was observed in both groups at 
6 months postoperatively. CAL gain was 3.16 ± 1.45 mm in the test group and 
2.77 ± 1.15 mm in the control group, showing no significant difference between 
groups. Radiographic bone fill was significantly greater in the test group (47.2%) than 
in the control group (29.3%). No significant difference in PROM between groups was 
observed.
Conclusions: At 6 months, no significant difference in CAL gain or PROM between 
the two treatments was observed, although combination therapy yielded an en-
hanced radiographic outcome.
K E Y W O R D S
bone graft, deproteinized bovine bone mineral, FGF-2, patient-reported outcome, periodontal 
regeneration, periodontitis
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in any medium, provided the original work is properly cited and is not used for commercial purposes.
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1  | INTRODUC TION
Thus far, many regenerative approaches have been introduced as 
therapy for periodontal defects. Of these, guided tissue regenera-
tion (GTR) and treatment with enamel matrix derivative (EMD) are 
widely performed and have shown considerable success (Heden 
& Wennstöm, 2006; Kao, Nares, & Reynolds, 2015; Rösing, Aass, 
Mavropoulos, & Gjermo, 2005; Tonetti et al., 2004).
Guided tissue regeneration using a collagen barrier membrane 
and deproteinized bovine bone mineral (DBBM) as a scaffold has 
been reported to yield significantly greater regeneration of peri-
odontal tissue, compared with that achieved by using each mate-
rial alone (Camelo et al., 2001; Nevins, Camelo, Nevins, Schenk, & 
Lynch, 2003). We previously reported favourable clinical outcomes 
at up to 2.5 years after combination therapy in the treatment of in-
trabony defects (Irokawa, Okubo, et al., 2017; Irokawa, Takeuchi, 
et al., 2017). However, such procedure involving the use of a barrier 
membrane is technique- sensitive and difficult to implement in some 
clinical situations. Notably, limitations have also been reported in 
the predictability of regenerative therapy, including bone grafts and 
GTR (Kao et al., 2015; Lin, Rios, & Cochran, 2015).
Attempts have been made to use bone substitutes with biolog-
ical agents, without barrier membranes. Clinical and histological 
analyses in humans have revealed that treatment using recombinant 
human platelet- derived growth factor (rhPDGF)- BB with bone al-
lograft yielded regeneration of periodontal tissues in intrabony de-
fects and Class II furcations at 9 months (Nevins et al., 2003). In a 
large multicenter randomized controlled trial (RCT), the use of beta- 
tricalcium phosphate (β- TCP) with rhPDGF- BB showed superior clin-
ical outcomes, compared with those achieved using β- TCP alone, at 
6 months (Nevins et al., 2005). Three- year extension results from a 
multicenter RCT showed that use of rhPDGF- BB with β- TCP yielded 
long- term clinical and radiographic improvements (Nevins et al., 
2013). Furthermore, a systematic review indicated that EMD used 
with bone graft materials may yield additional clinical improvements, 
as measured by gains in clinical attachment (CAL) and reductions 
in probing depth, compared with those achieved using EMD alone 
(Matarasso et al., 2015).
Fibroblast growth factor (FGF)- 2 exerts mitogenic and angio-
genic effects on mesenchymal cells in the periodontal ligament 
and has been shown to regenerate periodontal tissue in pre- clinical 
models (Ishii et al., 2013; Murakami et al., 2003; Oi, Ota, Yamamoto, 
Shibukawa, & Yamada, 2009; Takayama, Murakami, Shimabukuro, 
Kitamura, & Okada, 2001). Clinical trials have shown that trafermin, 
a form of recombinant human FGF- 2 (rhFGF- 2) is a safe and effective 
regenerative therapy in patients with periodontitis (Kitamura et al., 
2008, 2011, 2016). Notably, a novel regenerative therapy using 0.3% 
rhFGF- 2 received a formal pharmaceutical approval for clinical use in 
Japan in December 2016.
A comparative controlled clinical trial showed that, at 1 year 
postoperatively, the use of combination therapy, comprising EMD 
and DBBM, yielded greater improvements in clinical and radiograph-
ical outcomes than achieved using EMD alone (Zucchelli, Amore, 
Montebugnoli, & De Sanctis, 2003). Additionally, treatment using 
either EMD with DBBM or collagen membrane with DBBM showed 
similar results with respect to non- contained intrabony defects at 
1 year postoperatively (Iorio- Siciliano et al., 2014). However, no in-
formation is available regarding the effect of combined use of rhF-
GF- 2 with DBBM on periodontal healing.
This randomized, prospective study aimed to assess the use of 
rhFGF- 2 in combination with DBBM, compared with rhFGF- 2 alone, 
in the treatment of intrabony periodontal defects after an observa-
tion period of 6 months.
2  | MATERIAL S AND METHODS
2.1 | Study design
This prospective, parallel- arm, single- blind RCT, which involved 
periodontal regenerative therapy in patients with periodontitis, 
was conducted at two centres: Tokyo Dental College Suidobashi 
Hospital (Tokyo, Japan) and Tokyo Dental College Chiba Hospital 
(Chiba, Japan). This study was performed in accordance with the 
Declaration of Helsinki and was approved by the ethics committee 
of Tokyo Dental College (No.747). This RCT was registered (UMIN 
000025257) and followed Consolidated Standards of Reporting 
Trials (CONSORT) guidelines.
2.2 | Participants
Study participants, aged 20–79 years, were recruited consecu-
tively between January 2017 and February 2018 from among pa-
tients with moderate to severe chronic periodontitis (Armitage, 
1999; Page & Eke, 2007), all of whom had completed initial peri-
odontal therapy (IP). All participants consented to enrolment in 
this study.
Clinical Relevance
Scientific rationale for the study: Currently, information is 
limited regarding the clinical effect of combined use of rh-
FGF- 2 and bone graft on periodontal healing.
Principal findings: Treatment of intrabony defects using 
0.3% rhFGF- 2 with DBBM or rhFGF- 2 alone demonstrated 
comparable values of clinical attachment level gain at 6 
months postoperatively. The combination therapy yielded 
a greater radiographic bone fill than rhFGF- 2 alone. No sig-
nificant difference in PROM between groups was 
observed.
Practical implications: A significant improvement in perio-
dontal parameters can be expected by treatment using rh-
FGF- 2, with or without DBBM. Further investigations are 
necessary to clarify the true benefit of adding bone graft to 
rhFGF- 2 therapy.
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The inclusion criteria were as follows: presence of an intra-
bony defect depth of ≥ 3 mm in inter- proximal areas of teeth, inter- 
proximal sites with probing pocket depth (PPD) ≥ 4 mm, and a good 
level of plaque control [mean Plaque Control Record (O'Leary, Drake, 
& Naylor, 1972) ≤ 20%]. A sufficient level of keratinized gingiva had 
to be present for complete tissue coverage.
Exclusion criteria were the presence of diabetes mellitus; respi-
ratory and cardiovascular diseases; immunodeficiency; oral cancers 
and other cancers requiring treatment within the past 5 years; an 
ongoing smoking habit; allergy to medication; and/or previous or 
concurrent bisphosphonate or corticosteroid therapy. We excluded 
patients who were pregnant/lactating, as well as those with general 
contraindications for surgical therapy.
2.3 | Clinical examination
After obtaining systemic and dental histories, the following ex-
aminations were performed by calibrated examiners who were 
blinded to treatment assignment: PPD was measured using a 
periodontal probe with a constant force applier (Gram Probe #2, 
YDM, Tokyo, Japan). PPD and gingival recession (GR) were meas-
ured in 0.5 mm increments. CAL was determined by adding PPD 
values to GR values. Bleeding on probing (BOP) was assessed di-
chotomously, and tooth mobility (TM) was also evaluated (Miller, 
1950). These parameters were re- evaluated at 3 and 6 months 
postoperatively.
In an investigator meeting that was held before initiation of the 
study, six non- study volunteers participated in a calibration exercise. 
Intra- examiner reproducibility was assessed as the standard devia-
tion (SD) of the difference in triplicate measurements. All examiners 
achieved an SD of ≤ 0.4 mm for PPD. Inter- examiner variability was 
assessed as the difference from the gold standard examiner. The 
kappa value ranged from 0.75 to 0.80 for PPD.
2.3.1 | Radiographic examination
Periapical radiographs were taken using customized film holders as 
described previously (Irokawa, Okubo, et al., 2017). Prior to surgery, 
the depth of intrabony defects was estimated on radiographs; this 
was confirmed during surgery.
Assessment of radiographic changes (Schei et al., 1959) at the 
surgical sites was performed using a method previously described 
(Seshima et al., 2017). The difference in tooth axis height between 
the cemento- enamel junction and the defect bottom was defined as 
linear bone growth (LBG). The percentage of radiographic bone fill 
was determined by dividing the LBG by the baseline defect depth.
2.3.2 | Patient- reported outcome measure
An oral health- related quality of life (QoL) instrument, the OHRQL 
(Japanese version) (Saito et al., 2010, 2011), was used. Scoring was 
performed as previously described (Saito et al., 2010, 2011).
2.4 | Sample size estimation
Two treatment modalities were compared; a combined application 
of rhFGF- 2 + DBBM (test) and rhFGF- 2 alone (control). A sample size 
of 20 defects in each group was needed to achieve 80% power for 
detection of a clinically relevant difference in CAL gain of 1.1 mm 
between treatment groups, assuming a SD of 1.2 mm (Losada, 
González, Garcia, Santos, & Nart, 2017) with an alpha level 0.05 
(two- tailed). An overquotation of 10% was calculated to compensate 
for possible sample dropout. Thus, total sample size was 22 sites per 
group.
The unstratified design was used to calculate a two- sided 95% 
CI for the difference in CAL gain 6 months following surgery. The 
non- inferiority of test to control was accepted if the lower limit of 
the 95% CI for between- group difference was - 1.1 mm or greater. 




Periodontal defects were randomly assigned (1:1 ratio) to one of the 
two treatments, using a permuted block method by an individual 
who was not involved in other aspects of the study. Allocation to 
test or control groups was concealed from periodontists until the 
time of surgery. The assignment was performed using a sealed- 
envelope method, and patients were blinded to their assigned treat-
ment. If a patient had more than one defect, all defects received the 
same treatment assignment.
2.6 | Surgical procedures
Following local infiltration anaesthesia, defects were accessed using 
the papilla preservation techniques (Cortellini, Pini Prato, & Tonetti, 
1995, 1999). After debridement, defect morphology was recorded, and 
the depth and width of the intrabony defect were measured. Then, 
root surfaces underwent scaling and root planing, and the sites were 
rinsed with sterile saline. In the test group, 0.3% rhFGF- 2 [REGROTH® 
Dental Kit, 600 μg or 1200 μg in hydroxypropyl cellulose (HPC), Kaken 
Pharmaceutical, Tokyo, Japan] with DBBM (Geistlich Bio- Oss®, 0.25–
1.0 mm granules, Geistlich Pharma AG, Wolhusen, Switzerland) was 
applied to the defect. Prior to the application, the rhFGF- 2 solution 
was thoroughly mixed with DBBM in a sterile disposable dish. In the 
control group, rhFGF- 2 alone was applied to the defect. Immediately 
after application, the flaps were repositioned for complete closure 
and sutured with modified vertical mattress or interrupted sutures. 
Representative treatment cases are shown in Figure 1.
2.7 | Postsurgical care
Patients received antimicrobials (amoxicillin 750 mg/day or cefdinir 
300 mg/day) for 4 days. Standard pain medications were prescribed 
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as needed. Patients used a mouthwash twice per day. They gently 
cleaned the treated area with an ultrasoft toothbrush, beginning 
1 day postoperatively and continued for 4 weeks.
Sutures were removed after 10–14 days. The patients were then 
placed in supportive care programs.
2.8 | Statistical analysis
Fisher's exact test was used to assess categorical variables. The 
Mann–Whitney U test was used to compare other non- categorical 
demographic and baseline parameters between the two groups.
The primary outcome was the change in CAL at 6 months post-
operatively. Sites were compared with baseline, as well as between 
treatments. The data from the two centres were pooled for the pres-
ent analysis. The Friedman test with post hoc analysis was used to 
compare intra- group data over time. For intra- group comparisons of 
OHRQL scores over time, repeated measures analysis of variance 
(ANOVA) with Tukey–Kramer post hoc test was used to compare 
intra- group data over time, after testing on normal distribution of 
data.
Correlations between postoperative CAL gains and baseline 
variables were determined by Spearman correlation coefficient. 
Statistical software (InStat 3.10, GraphPad, La Jolla, CA, USA) 
was used. A p value of 0.05 was considered to indicate statistical 
significance.
3  | RESULTS
3.1 | Participant demographics and clinical 
parameters
A total of 34 patients were assessed for eligibility at two study cen-
tres; 44 sites in 32 patients were randomized between the two treat-
ment groups (Figure S1 flowchart).
Table 1 shows the participant demographics and baseline clini-
cal parameters. Five patients contributed more than one defect site. 
There were no significant differences in participant demographics 
and baseline parameters between groups.
3.2 | Clinical outcome
In each group, 22 sites of 16 patients completed the study. Healing was 
uneventful for all participants. There were no notable adverse events.
Characteristics of intrabony defects in the participants are sum-
marized in Table 2. Overall, there were no significant differences in 
maxillary versus mandibular sites, tooth type, defect morphology, 
F IGURE  1 Surgical procedure and outcomes. (a–g) 60- year- old female patient who received recombinant human fibroblast growth 
factor- 2 (rhFGF- 2) with deproteinized bovine bone mineral (DBBM; test group). (a) Preoperative radiograph. (b) Baseline clinical view 
(palatal). Probing pocket depth (PPD) at the mesial aspect of tooth #24 was 7 mm. (c) Intra- operative view. Defect depth 3 mm, width 5 mm. 
(d) After debridement and rinsing, the defect of #24 was filled with rhFGF- 2 formulation as well as DBBM that had been pre- saturated with 
rhFGF- 2. (e) Suturing. (f) Six- month follow- up view; PPD = 2 mm. (g) Six- month follow- up radiograph. (h- n) 53- year- old female patient who 
received rhFGF- 2 alone (control group); (h) Preoperative radiograph. (i) Baseline clinical view. PPD at the distal aspect of tooth #33 was 
7 mm. (j) Intra- operative view. Defect depth 5 mm, width 3 mm. (k) After debridement and rinsing, the defect of #33 was filled with rhFGF- 2. 
(l) Suturing. (m) Six- month follow- up view. PPD = 3 mm. (n) Six- month follow- up radiograph
(a) (b) (c) (d) (e)
(f) (g) (h) (i) (j)
(k) (l) (m) (n)
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or defect depth between groups. However, there was a statistically 
significant difference in the defect width (p = 0.007). The test group 
had significantly wider defects.
At 3 and 6 months postoperatively, marked improvements in 
CAL and PPD from baseline (post- IP) were noted in both groups 
(p < 0.001) (Table 3).
At 6 months postoperatively, CAL gains were 3.16 ± 1.45 mm in 
the test group and 2.77 ± 1.15 mm in the control group (Figure 2a). 
Non- inferiority of the test treatment to the control can be claimed, 
because the lower limit of the 95% CI for the difference in CAL gain 
was 0.39 ± 1.73 [95% CI (−0.38 to 1.15) was greater than −1.1 mm. No 
statistically significant inter- group difference was observed. In the test 
group, 22.7% of sites (n = 5) showed CAL gains of >4 mm; only 4.5% of 
sites (n = 1) in the control group showed this level of CAL gain (Table S1).
Reductions in PPD were 3.55 ± 1.35 mm in the test group and 
3.30 ± 1.20 mm in the control group; these did not significantly dif-
fer between groups.
3.3 | Correlation between CAL gain and 
baseline parameters
In a secondary analysis, relationships were assessed between post-
operative CAL gains at 6 months postoperatively and baseline (post-
 IP) variables. CAL gain at 6 months and baseline CAL or PPD values 
showed significantly positive correlations in both groups (Table S2). 
In the control group, a significant positive correlation was noted be-
tween CAL gain and the number of teeth at baseline. There was no 
significant correlation with other baseline variables in either group.
3.4 | Radiographic outcome
In both groups, a significant increase was observed in radiographic 
bone fill from 3 months to 6 months postoperatively (Table 3). At 
6 months, the mean value for the radiographic bone fill was signifi-
cantly greater in the test group (47.2%) than in the control group 
(29.3%) (p = 0.013) (Figure 2b).
rhFGF- 2 rhFGF- 2 + DBBM Difference
Age (years; mean ± SD) 50.0 ± 10.9  
(range, 28–69)




Men 6 7 N.S.a
Women 10 9
No. of teeth (mean ± SD) 25.7 ± 3.9 26 ± 2.2 N.S.
Clinical attachment level (CAL) (mm; mean ± SD)
Full- mouth 3.30 ± 0.59 3.30 ± 0.63 N.S.
Reference siteb 7.07 ± 1.56 7.57 ± 1.64 N.S.
Probing pocket depth (PPD) (mm; mean ± SD)
Full- mouth 2.86 ± 0.50 3.00 ± 0.53 N.S.
Reference siteb 6.02 ± 1.33 6.32 ± 1.25 N.S.
Gingival recession (GR) (mm; mean ± SD)
Reference siteb 1.23 ± 1.51 1.25 ± 1.38 N.S.
Bleeding on probing (BOP) positive (%)
Reference siteb 72.7 77.3 N.S.a
Tooth mobility (TM) (mean ± SD)
Reference toothb 0.18 ± 0.50 0.22 ± 0.43 N.S.
Note. Differences were assessed by the Mann–Whitney U test (aFisher's exact test). bn = 22 per 
group.
TABLE  1 Participant demographics 
and baseline parameters
TABLE  2 Distribution and configuration of intrabony defects
Intrabony defect rhFGF- 2 rhFGF- 2 + DBBM
Position [n (%)]
Maxilla 9 (41) 10 (45.5)
Mandible 13 (59) 12 (54.5)
Anterior teeth 7 (31.8) 2 (9.1)
Premolars 6 (27.3) 6 (27.3)
Molars 9 (40.9) 14 (63.6)
Morphology [n (%)]
1- wall 3 (13.6) 2 (9.1)
2- wall 5 (22.7) 5 (22.7)
3- wall 8 (36.4) 7 (31.8)
Combination 6 (27.2) 8 (36.4)
Depth (mm; 
mean ± SD)
4.66 ± 1.76  
(range, 3.0–11.0)




2.80 ± 0.75  
(range, 2.0–5.0)
3.89 ± 1.81*** 
(range, 2.0–10.0)
Note. ***p = 0.007, Mann–Whitney U test. 
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3.5 | Effect of defect configurations
When 6- month postoperative CAL gains were compared between 
1–2- wall and 3- wall defects, no significant differences were found in 
either treatment group (Table 4). Similarly, no significant differences 
in radiographic bone fill were found between 1–2- wall defects and 
3- wall defects in either group.
3.6 | Patient- reported outcome measure (PROM)
In both groups, IP yielded a significant improvement in total OHRQL 
score (Figure 3). Compared with baseline (post- IP) total OHRQL 
score, no significant changes were observed at 3 or 6 months post-
operatively. At each timepoint, no significant difference in total 
OHRQL score was observed between groups.
4  | DISCUSSION
To the best of our knowledge, this is the first RCT to evaluate the use 
of rhFGF- 2 with DBBM, compared with rhFGF- 2 alone in the treat-
ment of intrabony defects, using both clinical and patient- centred 
outcomes. We have shown no significant difference in CAL gain be-
tween the two groups at 6 months postoperatively. The combination 
TABLE  3 Clinical and radiographic outcomes of treated sites (Total n = 44; n = 22 per group)
Variable/Group Baseline 3 months
Change from baseline 
to 3 months 6 months
Change from baseline 
to 6 months
Change from 3 
to 6 months
CAL (mm)
rhFGF- 2 7.07 ± 1.56 
(6.38–7.76)
4.75 ± 1.24 
(4.20–5.30)
p < 0.001 4.29 ± 1.33 
(3.70–4.89)
p < 0.001 N.S.
rhFGF- 2 + DBBM 7.57 ± 1.64 
(6.80–8.39)
4.50 ± 1.59 
(3.80–5.20)
p < 0.001 4.41 ± 1.40 
(3.80–5.03)
p < 0.001 N.S.
Difference N.S. N.S. N.S.
PPD (mm)
rhFGF- 2 6.02 ± 1.33 
(5.43–6.61)
3.05 ± 0.80 
(2.69–3.40)
p < 0.001 2.73 ± 0.84 
(2.35–3.10)
p < 0.001 N.S.
rhFGF- 2 + DBBM 6.32 ± 1.25 
(5.76–6.87)
2.84 ± 0.82 
(2.48–3.21)
p < 0.001 2.77 ± 0.72 
(2.45–3.09)
p < 0.001 N.S.
Difference N.S. N.S. N.S.
GR (mm)
rhFGF- 2 1.23 ± 1.51 
(0.56–1.90)
1.57 ± 1.38 
(0.96–2.18)
N.S. 1.39 ± 1.34 
(0.80–1.98)
N.S. N.S.
rhFGF- 2 + DBBM 1.25 ± 1.38 
(0.64–1.86)
1.68 ± 1.41 
(1.06–2.31)
N.S. 1.64 ± 1.33 
(1.05–2.23)
N.S. N.S.
Difference N.S. N.S. N.S.
BOP positive (%)
rhFGF- 2 72.7 22.7 p = 0.002 9.1 p < 0.001 N.S.
rhFGF- 2 + DBBM 77.3 4.5 p = 0.001 4.5 p < 0.001 N.S.
Differencea N.S. N.S. N.S.
TM
rhFGF- 2 0.18 ± 0.50 
(0–0.40)
0.09 ± 0.29 
(0–0.22)
N.S. 0.09 ± 0.29 
(0–0.22)
N.S. N.S.
rhFGF- 2 + DBBM 0.22 ± 0.43 
(0.09–0.04)
0.05 ± 0.21 
(0–0.14)
N.S. 0.05 ± 0.21 
(0–0.14)
N.S. N.S.
Difference N.S. N.S. N.S.
RBF (%)
rhFGF- 2 – 21.8 ± 11.9 – 29.3 ± 13.3 – p = 0.001
rhFGF-2 + DBBM – 39.3 ± 17.6 – 47.2 ± 16.0 – p < 0.001
Difference p = 0.001 p = 0.001
Notes. Data shown as mean ± SD (95% Confidence Interval) (except for BOP and RBF). Inter- group difference at each time point was assessed by the 
Mann–Whitney U test. Intra- group difference over time was assessed by the Friedman test with Dunn's post- test (aCategorical data were assessed by 
Fisher's exact test).
CAL: clinical attachment level; PPD: probing pocket depth; GR: gingival recession; BOP: bleeding on probing; TM: tooth mobility; RBF: radiographic 
bone fill.
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therapy yielded a greater radiographic bone fill than rhFGF- 2 alone. 
Furthermore, no significant difference in PROM between groups 
was noted, as assessed by total OHRQL scores.
In clinical trials regarding treatment of periodontal defects, the 
use of rhFGF- 2 alone has yielded clinically favourable outcomes 
(Kitamura et al., 2008, 2011, 2016). This is remarkable considering 
that, as in the present study, prior investigators used 0.3% rhF-
GF- 2 with HPC, a gel- like base material, without the support of 
other scaffolds such as bone graft materials (Li et al., 2017). To 
further explore the regenerative potential of rhFGF- 2, the ef-
fects of its combined use with β- TCP have been studied. Oi et al. 
(2009) reported that, in dogs, rhFGF- 2 + β- TCP treatment yielded 
greater levels of new bone and cementum formation compared 
with treatment with rhFGF- 2- alone. In a previous study, we used 
rhFGF- 2 + β- TCP for root coverage in a dog model (Ishii et al., 
2013); we found that the combination therapy enhanced forma-
tion of new bone and cementum. Thus, we speculated that β- TCP 
provided a local environment that was suitable for periodontal re-
generation. Moreover, Anzai et al. (2010) reported that the use of 
FGF- 2 with β- TCP increased the bone mineral contents of 1- wall 
defects in a dog model, compared with the use of β- TCP alone. In a 
multicenter RCT evaluating the treatment of intrabony periodon-
tal defects, the use of 0.3% and 0.4% rhFGF- 2 with β- TCP showed 
an improved success rate (based on changes in CAL and LBG) at 
6 months postoperative, compared with β- TCP alone (Cochran 
et al., 2016). The reported CAL gain achieved using 0.3% rhFGF- 2 
with β- TCP was 3.0 ± 1.4 mm at 6 months; this was comparable 
to our present findings using rhFGF- 2 with DBBM (3.2 ± 1.5 mm). 
However, the participants in the prior study exhibited consider-
ably greater baseline mean CAL (8.3 mm) and PPD (7.9 mm) values, 
compared with those (CAL 7.6 mm, PPD 6.3 mm) in the present 
study. In this study, the CAL gain was significantly positively 
correlated with baseline CAL or PPD values, which is consistent 
with the previous reports (Cortellini, Pini Prato, & Tonetti, 1993; 
Irokawa, Okubo, et al., 2017; Saito, Nanbu, Nagahata, & Yamada, 
2008). This indicates that CAL gain after regenerative therapy de-
pends on the initial level of destruction, which has to be taken into 
account when comparing data from different studies.
Regarding the effect of the combined use of rhFGF- 2 with de-
mineralized bone matrix (DBM), Hagino, Hamada, and Amemiya 
(2001) showed that the use of 200 μg of rhFGF- 2 with DBM yielded 
early new bone formation in segmental bone defects in a rabbit 
model. Notably, these authors suggested that when DBM was used 
F IGURE  2 Clinical attachment level (CAL) gain (a) and 
radiographic bone fill (RBF) (b) at 6 months. Scatter plots showing 
individual data with mean (middle line) and standard deviation 
(error bars).***p = 0.001 by Mann–Whitney U test
Defect rhFGF- 2 Difference rhFGF- 2 + DBBM Difference
CAL gain (mm) 3- wall 2.78 ± 0.79 N.S. 3.43 ± 2.09 N.S.
1- 2- wall 2.77 ± 0.38 3.11 ± 1.11
RBF (%) 3- wall 29.4 ± 11.2 N.S. 41.5 ± 13.0 N.S.
1- 2- wall 29.2 ± 15.1 49.9 ± 17.0
Notes. Data are shown as mean ± SD.
CAL: clinical attachment level; RBF: radiographic bone fill.
TABLE  4 Clinical attachment gain and 
radiographic bone fill at 6 months 
postoperatively, based on defect 
configuration
F IGURE  3 Change in total OHRQL scores over time. **p < 0.01, 
***p < 0.001, significantly different from those at initial visit, by the 
repeated measures analysis of variance with Tukey–Kramer post 
hoc test. No significant difference was noted between the two 
different treatment groups at any time point. IP: initial periodontal 
therapy
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as a carrier, a single local administration of rhFGF- 2 at an appropri-
ate concentration may be effective for bone formation; moreover, 
the release of FGF- 2 over an extended period may not be neces-
sary. When DBBM was used with EMD in vitro, the investigators 
observed enhanced attachment, proliferation and differentiation 
of osteoblasts and periodontal ligament cells on DBBM granules 
(Miron et al., 2012). In a study using concentrated growth factors 
with DBBM, persistent releases of cytokines, including FGF- 2, was 
observed over a period of 28 days (Yu, Wang, Liu, & Qiao, 2018). 
These data indicate the potential for use of DBBM as a scaffold or 
carrier for growth factors. The adsorption of rhFGF- 2 to DBBM, as 
well as specific cell behaviours on DBBM with rhFGF- 2 should be 
further explored.
There are multiple opinions within the literature regarding the 
effect of bone substitutes in combination regenerative therapy. In 
a multicenter RCT, Jepsen et al. (2008) reported the treatment of 
intrabony defects using EMD with alloplast or EMD alone; both 
approaches showed similar results after 6 months. The similar re-
sults were confirmed at 36 months after treatment (Hoffmann, 
Al- Machot, Meyle, Jervøe- Storm, & Jepsen, 2016). Pietruska et al. 
(2012) also evaluated clinical outcomes following treatment of in-
trabony defects using EMD with synthetic bone graft or EMD alone; 
they concluded that, in 2- and 3- wall defects, combination therapy 
did not show any advantage after 4 years. In contrast, a systematic 
review revealed that the use of EMD with bone grafts may enhance 
clinical outcomes (Matarasso et al., 2015). According to a clinical 
practice guideline of the Japanese Society of Periodontology (JSP, 
2016), there is no clear evidence of an additional effect when bone 
graft is applied in combination with GTR or EMD. The guideline 
states that careful consideration should be given to this type of ap-
plication. In the present study, the addition of DBBM to rhFGF- 2 
therapy did not yield a significantly greater CAL gain at 6 months 
(the primary endpoint). Of concern was the statistically significant 
difference (p = 0.007) in baseline defect width for the test (3.89 mm) 
and the control (2.80 mm). This may be one reason for no signifi-
cant difference in CAL gains found between groups. However, the 
radiographic bone fill (a secondary endpoint) in the test group was 
significantly greater than in the control group. The influence of dif-
ference in the initial defect width on the clinical outcome remains to 
be clarified.
Tonetti et al. (2002) reported that defect morphology (i.e. 
number of bone walls) influenced the clinical results of regenera-
tive therapy with EMD. Trombelli and Farina (2008) reported that 
EMD does not maintain a space itself when used in non- contained 
defects. According to an evidence- based decision tree by 
Cortellini and Tonetti (2000), the combined use of supportive or 
filling materials is recommended to treat wide defects and/or non- 
contained defects. Because the rhFGF- 2 formulation in the pres-
ent study used HPC, a gel- like base material, its ability for space 
maintenance may also be limited. Therefore, we initially antici-
pated that the use of rhFGF- 2 with DBBM might provide superior 
clinical results, compared with rhFGF- 2 alone, especially in more 
compromised sites (i.e. non- contained defects). However, when 
we compared the results in 3- wall defects and 1–2- wall defects, 
no significant difference was noted in CAL gain or radiographic 
bone fill. There are two possible reasons for this phenomenon: (1) 
rhFGF- 2 alone is clinically effective for non- contained defects; (2) 
the present study was underpowered to detect this difference. 
Considering that 1- wall defects comprised only 14% and 9% of 
sites in the test and control groups, respectively, both possibilities 
should be examined.
Subjective oral health- related QoL assessments are considered 
true endpoints when evaluating the effect of periodontal treatment 
(Hujoel, 2004). In the present study, oral health- related QoL was 
assessed as a PROM. Consistent with the findings of our previous 
study (Makino-Oi et al., 2016), patients’ oral health- related QoL 
scores were significantly improved after IP. Regenerative therapy 
using rhFGF- 2 alone or rhFGF- 2 combined with DBBM yielded no 
significant changes in oral health- related QoL, indicating that neither 
surgical intervention positively or negatively affected patients’ oral 
health- related QoL. Furthermore, patients’ perceptions of the rhF-
GF- 2 treatment and healing process may not have been impaired by 
the addition of DBBM.
There were limitations in this study. For example, the test sites 
had wider defects at baseline, but our statistical analysis did not in-
clude an adjustment for this. Because the number of non- contained 
defects was limited, the impact of the number of residual walls on 
treatment outcomes may not have been appropriately evaluated. 
Moreover, because the observation period of 6 months is relatively 
short, a longer follow- up is needed.
In conclusion, treatment of intrabony defects with rhFGF- 2, with 
or without DBBM, yielded significant improvements in periodon-
tal parameters at 6 months, relative to baseline measurements. No 
significant difference in CAL gain was observed between groups, 
although combination therapy yielded an enhanced radiographic 
outcome. There was no significant difference in PROM between 
groups. Further longitudinal investigation with a larger number of 
participants should identify the characteristics of cases that would 
benefit most from combined treatment using rhFGF- 2 and DBBM.
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